Acadian Asset Management’s Oric Pharmaceuticals ORIC Stock Holding History

Acadian Asset Management’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$33K	Buy	+2,679	New	+$30.4K	﹤0.01%	1900
2024 Q4	–	Sell	-2,309	Closed	-$23K	–	2022
2024 Q3	$23K	Buy	+2,309	New	+$22.8K	﹤0.01%	1960
2023 Q4	–	Sell	-22,691	Closed	-$137K	–	1780
2023 Q3	$137K	Sell	22,691 -147,797	-87%	-$1.21M	﹤0.01%	1258
2023 Q2	$1.32M	Buy	170,488 +39,833	+30%	+$226K	0.01%	814
2023 Q1	$744K	Buy	130,655 +2,804	+2%	+$14.7K	﹤0.01%	954
2022 Q4	$752K	Hold	127,851	–	–	﹤0.01%	920
2022 Q3	$408K	Buy	127,851 +13,635	+12%	+$54.6K	﹤0.01%	1044
2022 Q2	$511K	Buy	114,216 +108,709	+1,974%	+$434K	﹤0.01%	964
2022 Q1	$29K	Buy	+5,507	New	+$49.6K	﹤0.01%	1525

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Acadian Asset Management's ORIC Position: Q1 2026 in Review

Acadian Asset Management opened a new position in Oric Pharmaceuticals (ORIC) in Q1 2026: 2,679 shares worth $33K. The stake represents ﹤0.01% of the portfolio and ranks #1900 among its holdings. This is a return to the name: Acadian Asset Management previously reported a position in ORIC as recently as Q3 2024.

Acadian Asset Management first reported a position in ORIC in Q1 2022 and has held it in 9 quarters since. The position peaked at $1.32M in Q2 2023. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

Acadian Asset Management held 2,679 shares of Oric Pharmaceuticals worth $33K as of Q1 2026.
Oric Pharmaceuticals was a new Acadian Asset Management position in Q1 2026.
Oric Pharmaceuticals made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1900 holding.
Acadian Asset Management first reported a position in Oric Pharmaceuticals in Q1 2022 and has held it in 9 quarters since.
Acadian Asset Management's Oric Pharmaceuticals position peaked at $1.32M in Q2 2023.
182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.